We are live on
!
Find out more
HP
Harbourvest Partners Portfolio holdings
AUM
$101M
1-Year Est. Return
38.13%
This Fund
S&P 500
This Quarter
Est. Return
-7.76%
1 Year Est. Return
-38.13%
3 Year Est. Return
-6.18%
5 Year Est. Return
-50.73%
10 Year Est. Return
+34.53%
AUM
$295M
AUM Growth
-$57.6M
(-16%)
Cap. Flow
-$12.7M
Cap. Flow
% of AUM
-4.32%
Top 10 Holdings %
Top 10 Hldgs %
81.19%
Holding
63
New
3
Increased
2
Reduced
12
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
|
+$8.86M |
| 2 |
Sprinklr
CXM
|
+$3.16M |
| 3 |
Sana Biotechnology
SANA
|
+$740K |
| 4 |
QuantumScape Corp
QS
|
+$346K |
| 5 |
Nano X Imaging
NNOX
|
+$37.8K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWI
SolarWinds Corporation Common Stock
SWI
|
+$6.38M |
| 2 |
Affirm
AFRM
|
+$4.39M |
| 3 |
N-able
NABL
|
+$3.67M |
| 4 |
monday.com
MNDY
|
+$2.22M |
| 5 |
Robinhood
HOOD
|
+$2.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 56.94% |
| 2 | Consumer Discretionary | 25.68% |
| 3 | Healthcare | 9.49% |
| 4 | Energy | 2.46% |
| 5 | Communication Services | 2.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Seres Therapeutics
MCRB
$46.3M
| $117K | 0.04% |
2,468
| – | – |
|
52
Rallybio
RLYB
$85.3M
| $73.7K | 0.03% |
2,735
| – | – |
|
53
PMV Pharmaceuticals
PMVP
$60.3M
| $70.8K | 0.02% |
11,533
| – | – |
|
54
Century Therapeutics
IPSC
$395M
| $58K | 0.02% |
29,018
| – | – |
|
|
55
Nano X Imaging
NNOX
$67.2M
| $24.1K | 0.01% |
+3,678
| New | +$37.8K |
|
|
ASTR
56
DELISTED
Astra Space, Inc. Class A Common Stock
ASTR
| $23K | 0.01% |
12,444
| – | – |
|
57
Aligos Therapeutics
ALGS
$26.7M
| $14K | ﹤0.01% |
751
| – | – |
|
58
NextCure
NXTC
$20.5M
| $13K | ﹤0.01% |
837
| – | – |
|
|
ONTF
59
DELISTED
ON24
ONTF
| – | – |
-109,210
| Closed | -$887K |
|
60
Rhythm Pharmaceuticals
RYTM
$7.25B
| – | – |
-5,639
| Closed | -$93K |
|
|
LOV
61
DELISTED
Spark Networks SE American Depositary Shares
LOV
| – | – |
-52,175
| Closed | -$16.4K |
|
|
GRNA
62
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
| – | – |
-48,835
| Closed | -$14.6K |
|
|
SGTX
63
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| – | – |
-56,979
| Closed | -$1.28M |
|
Similar funds
VCM
TCI
RPC
XC
AWA
HWM
CG
ROP
Harbourvest Partners's Q3 2023 Portfolio in Review
As of Q3 2023, Harbourvest Partners held 63 positions worth $295M, down 16% from $352M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Harbourvest Partners withdrew a net $12.7M in Q3 2023, closing 5 positions and reducing 12 holdings. Its most notable exit was Sigilon Therapeutics, Inc. Common Stock, an estimated $1.28M position sold in full.
By sector, the portfolio is most concentrated in Technology at 57% of assets, down from 57% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Harbourvest Partners opened a new position in Sprinklr worth $3.05M.
- Harbourvest Partners's largest Q3 2023 buy was Sprinklr: 220,526 shares worth $3.05M.
- Harbourvest Partners added most to Evelo Biosciences, Inc. Common Stock in Q3 2023, an estimated $8.86M increase.
- Harbourvest Partners's biggest Q3 2023 reduction was SolarWinds Corporation Common Stock, cutting an estimated $6.38M.
- Harbourvest Partners fully exited Sigilon Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $1.28M.
- Harbourvest Partners's ten largest holdings make up 81% of its $295M portfolio in Q3 2023.
- Harbourvest Partners opened 3 new positions and closed 5 in Q3 2023.
- Harbourvest Partners's portfolio value fell 16% quarter-over-quarter to $295M.
Based on Harbourvest Partners's 13F filing for Q3 2023, filed 14 Nov 2023.